Suzhou, China, October 27, 2020 - Suzhou Abogen Biosciences Co., Ltd. (“Abogen”) announces today that it has completed RMB 150 million in Series A financing, which was led by SDIC Venture Capital, GL Ventures, and Chengdu Kanghua Biological Products Co., Ltd.

After this round of financing, Abogen will better develop its technological platform and R&D center. By building an industrial-leading mRNA technological platform, Abogen will speed up the clinical trials of its mRNA vaccine candidate and sustainably expand its innovative product pipelines to provide more effective vaccines and innovative mRNA drugs for patients worldwide.

About Abogen

Abogen is a clinical-stage biotechnology company focused on advancing mRNA-based therapeutics for the treatment of cancer and other infectious diseases. Since its establishment in January 2019, Abogen has developed its own mRNA technology platform and proprietary delivery system which empowers the development of a series of drug product candidates including vaccines for infectious diseases and therapies for cancer.